Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
about
Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?Advanced magnetic resonance imaging of the physical processes in human glioblastoma.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Multimodality intraoperative MRI for brain tumor surgery.Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Delayed contrast extravasation MRI: a new paradigm in neuro-oncologyUse of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survivalMR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidenceMRI perfusion in determining pseudoprogression in patients with glioblastoma.Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.Amino acid PET and MR perfusion imaging in brain tumours.Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.Post-embolisation susceptibility changes in giant meningiomas: multiparametric histogram analysis using non-contrast-enhanced susceptibility-weighted PRESTO, diffusion-weighted and perfusion-weighted imaging.Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence.Which is the best advanced MR imaging protocol for predicting recurrent metastatic brain tumor following gamma-knife radiosurgery: focused on perfusion method.Utility of intravoxel incoherent motion MR imaging for distinguishing recurrent metastatic tumor from treatment effect following gamma knife radiosurgery: initial experience.Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice.Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.Contrast-Enhanced Perfusion MR Imaging to Differentiate Between Recurrent/Residual Brain Neoplasms and Radiation Necrosis
P2860
Q30418915-F49B7057-4919-4AC7-9D71-D3264BA08D5DQ30847284-B6BBF246-EDC7-4663-A7D5-22473A687838Q30938805-638B56C3-4586-4A0D-8473-78E3C4CA7FA9Q33718297-8E036DD1-AC94-4D6F-9BC8-D69DC9B25617Q34389144-5973E12C-9454-458D-9D81-6D8D2B042510Q34517492-481B7E80-E360-48B1-80DF-9956D1DA4986Q35771783-3BC3178C-C298-4388-B52D-64F76A09ACE8Q35788925-E509CB46-2957-4BB4-A49A-5EF4C41B9BDFQ35914541-0F98D94F-5B94-4F63-AF6D-D23B7456E3A4Q36048166-58ACFBDF-BAB5-4517-84DF-5F1DE63EFD7BQ36097886-0650D798-BA08-4A21-B67A-7469905A00F3Q36265476-860EF639-5F62-4263-A0A4-3F6FAA83D578Q36324977-56B02380-0173-41D2-88B1-F983E0AEC3F6Q36378153-11CBCDA9-1BB6-4A6E-B6EE-CAAD492298AEQ36501587-6ED86A53-070E-4D4C-950B-92A55951EC54Q36515232-11674DD3-E8F6-400C-BC09-43F0A2FEABCCQ36585386-7EB7FBC5-00C7-4D1C-8B89-920B103ED726Q37523107-CDCFF8DB-9B26-4E18-8A7E-9440F1C03E9EQ38691946-EDF3385C-565F-4DE3-A5A2-726CF5546B71Q41961216-49476FAA-A6CA-4BA1-A78A-5007D1C64A12Q44669124-12CC909C-3A55-478F-90DE-A080CAF421CBQ45179517-B55E1B2B-FA46-4D21-843F-34C1D43BFA46Q47825877-3F372822-EDCD-4BE2-905E-6FD9669A832FQ48213178-3C184F55-3406-443E-82F5-3271D96C9189Q48374780-7202D3E7-C8C2-4540-A9BB-429A51F76DCAQ48692358-8D041B8C-7DCD-41C9-9BD1-EDF3F516086DQ51416304-C04FC2DC-D52D-4933-8FED-0E5CD0E9DCC5Q52148215-DFB04916-1F1F-4200-AFC8-66F42407C791Q55528783-AF5AB578-C068-4507-9FE1-1AB7A4BE2EC0
P2860
Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@ast
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@en
type
label
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@ast
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@en
prefLabel
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@ast
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@en
P2093
P50
P1433
P1476
Posttreatment recurrence of ma ...... nt histologic volume fraction.
@en
P2093
Elias R Melhem
Emerson L Gasparetto
Jaroslaw Krejza
Jason Huse
John H Woo
Robert Lustig
Ronald L Wolf
Sohil H Patel
P304
P356
10.1148/RADIOL.2502071444
P407
P577
2009-03-01T00:00:00Z